Déjà vu for Aveo and tivozanib
As the plot thickens around the trigger for Aveo’s equity raise, the EU regulator considers pulling the group's renal cancer drug from the market.
Alkermes gets decisive thumbs down
ALKS 5461 is headed back to the clinic or scrapheap, raising questions over whether Alkermes should remain in mental health drug development.
Amicus’s Pompe disease setback doesn’t dent gene therapy enthusiasm
The FDA asks Amicus for more data on its Pompe disease candidate, but the company is already looking towards a Fabry disease gene therapy, and has made a remarkable…
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.